Equities

WAVE Life Sciences Ltd

WAVE Life Sciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.68
  • Today's Change-0.26 / -4.38%
  • Shares traded1.78m
  • 1 Year change+7.98%
  • Beta-1.1312
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).

  • Revenue in USD (TTM)110.50m
  • Net income in USD-73.74m
  • Incorporated2012
  • Employees266.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Adaptive Biotechnologies Corp168.77m-213.47m685.75m709.00--2.84--4.06-1.47-1.471.161.640.25014.745.03238,033.80-31.65-19.69-36.63-22.0654.7767.18-126.55-122.273.84--0.3536---8.1125.06-12.52--11.11--
Ironwood Pharmaceuticals, Inc.400.57m9.21m686.88m267.0099.51--74.491.710.04320.04322.43-2.010.8021--4.521,500,244.001.44-4.542.21-5.20----1.79-7.81--4.602.07--7.835.02-672.50--160.10--
Wave Life Sciences Ltd110.50m-73.74m708.51m266.00------6.41-0.5796-0.57960.92750.03590.5036----415,413.50-33.49-56.98-117.16-102.38-----66.50-353.20----0.00--3,005.1051.0464.46---35.44--
ProKidney Corp0.00-38.68m712.60m163.00---------0.5905-0.59050.00-7.730.00----0.00-27.97------------------0.0003------67.17------
Astria Therapeutics Inc0.00-93.24m713.78m59.00--2.76-----2.30-2.300.006.320.00----0.00-32.43-64.48-33.78-68.34------------0.00-------40.62------
MBX Biosciences Inc0.00-47.20m718.30m36.00---------1.48-1.480.001.71------0.00--------------------0.00-------24.60------
Stoke Therapeutics Inc15.16m-103.57m723.91m110.00--2.96--47.76-2.18-2.180.3174.640.0537--68.74137,790.90-36.68-31.62-41.57-33.92-----683.31-1,775.50----0.00---29.22---3.59--11.56--
Savara Inc0.00-75.29m739.06m37.00--6.10-----0.4317-0.43170.000.73610.00----0.00-58.02-36.86-62.14-39.54-------102,587.50----0.2066-------43.38--15.91--
Annexon Inc0.00-115.16m742.75m71.00--2.05-----1.22-1.220.003.420.00----0.00-36.04-44.06-38.13-46.93------------0.00------5.43--62.56--
Replimune Group Inc0.00-220.01m745.39m331.00--1.75-----3.27-3.270.006.240.00----0.00-38.64-29.08-41.09-30.56------------0.143-------23.82--16.84--
Scholar Rock Holding Corp0.00-203.85m751.51m150.00--5.62-----2.22-2.220.001.670.00----0.00-79.66-38.14-89.70-44.31-------647.95----0.2726---100.00---23.26---45.61--
Zenas Biopharma Inc50.00m-54.76m756.06m114.00------15.12-1.38-1.381.264.04------595,238.10-------------109.51------0.00------68.88------
Arbutus Biopharma Corp10.06m-77.09m758.90m73.00--6.20--75.43-0.4416-0.44160.05750.64880.0597--4.59137,821.90-45.77-52.62-53.21-58.11-----766.20-537.81----0.00---53.5125.00-4.89---2.40--
AbCellera Biologics Inc33.06m-153.30m763.18m586.00--0.6870--23.09-0.5254-0.52540.11333.770.0224--0.80856,407.85-10.396.08-11.116.67-----463.7724.69----0.000.00-92.1733.91-192.35--70.96--
Data as of Sep 20 2024. Currency figures normalised to WAVE Life Sciences Ltd's reporting currency: US Dollar USD

Institutional shareholders

51.42%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 12 Aug 202418.22m14.61%
Maverick Capital Ltd.as of 30 Jun 20247.67m6.15%
M28 Capital Management LPas of 30 Jun 20246.16m4.94%
BlackRock Fund Advisorsas of 30 Jun 20246.10m4.89%
Adage Capital Management LPas of 30 Jun 20245.36m4.30%
683 Capital Management LLCas of 30 Jun 20245.33m4.27%
Invus Public Equities Advisors LLCas of 30 Jun 20244.57m3.66%
Bellevue Asset Management AGas of 30 Jun 20244.09m3.28%
Kynam Capital Management LPas of 30 Jun 20243.98m3.19%
PRIMECAP Management Co.as of 30 Jun 20242.66m2.14%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.